CD4 and neoplasm: None of the other immunological blood parameters tested (percent CD4+, CD8+ T cells, expression of PD-1 on CD4+, CD8+ T cells, expression of PD-L1 on CD4+ T cells both pretreatment and at day 6, as well as their change) showed significant association with tumor response to RT+L19–IL2 or RT+L19–IL2+anti-PD-L1 or RT+anti-PD-L1.